Emily Wood, DO
Hospitalist · Saint Louis, MONPI 1265743025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Dexcom, Inc. at 24.5% of the total. Among hospitalist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$822
- Sequel Med Tech, LLC$460
- Abbott$440
- Medtronic$414
- Novo Nordisk$392
- Lilly USA, LLC$341
- plus $481 from 10 others
What the payments were for
- Food & beverage$3,22496%
- Education$1264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 65 | $822 |
| Sequel Med Tech, LLC | 16 | $460 |
| Abbott | 17 | $440 |
| Medtronic(2 entities) | 6 | $414 |
| Novo Nordisk | 13 | $392 |
| Lilly USA, LLC | 11 | $341 |
| Tandem Diabetes Care, Inc. | 2 | $124 |
| Mannkind Corporation | 12 | $123 |
| AstraZeneca | 5 | $82 |
| BETA Bionics, Inc. | 2 | $35 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
| Boehringer Ingelheim | 1 | $23 |
| Insulet Corporation | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TWIIST$149
- DEXCOM G7 GSS (161)$143
- MINIMED 770G$139
- MOUNJARO$123
- Wegovy$121
- t:slim X2 Insulin Pump with Control-IQ$116
- FREESTYLE LIBRE 3$113
How this compares
$3,350 in reported general payments places this provider in the 95th percentile of 712 hospitalist providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 356 | $436,647 |
| TrulicityDulaglutide | 126 | $137,066 |
| JardianceEmpagliflozin | 114 | $132,206 |
| MounjaroTirzepatide | 67 | $81,986 |
| FarxigaDapagliflozin Propanediol | 61 | $61,488 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $19,769 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $17,722 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $14,719 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $11,481 |
| DapagliflozinDapagliflozin Propanediol | 17 | $8,658 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $7,500 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $6,661 |
| HumalogInsulin Lispro | 17 | $5,384 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 36 | $3,442 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $3,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $392 | $436,647356 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $341 | $224,435210 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $23 | $156,589143 claims |
| AstraZenecaFarxiga | $82 | $61,48861 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 712 hospitalist providers in Missouri.
Other hospitalist in Saint Louis
- Gian MusarraSaint Louis$25K
- Ghassan DaherSaint Louis$23K
- Marsha SchulteSaint Louis$23K
- Ijeoma NwelueSaint Louis$12K
- Arun MannemSaint Louis$6K
- Vasanthan KuppuswamySaint Louis$5K
- Yamuna KondapallySaint Louis$5K
- Basem AbdeenSaint Louis$4K
- John MwangiSaint Louis$4K
- Tariq HalasaSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.